Middleby names Steve Spittle to succeed Tim FitzGerald as CEO on April 1, 2027

MIDD•2026-11-05

Middleby appointed Steve Spittle to succeed Tim FitzGerald as CEO, effective April 1, 2027. Spittle became president on November 5, 2026, and will join the board when FitzGerald steps down as a director.

1. CEO succession

Middleby appointed Steve Spittle to succeed Tim FitzGerald as CEO, effective April 1, 2027. Spittle, previously chief commercial officer, became president on November 5, 2026; he joined the company in 2010. On April 1, 2027, Spittle will join the board as FitzGerald steps down as a director.

Middleby names Steve Spittle to succeed Tim FitzGerald as CEO on April 1, 2027

1. CEO succession

Related News

Fate Therapeutics Q3 2026 net loss narrows year over year to $30.69 million

Astec Industries Q3 net loss more than doubles year over year to $12.2 million

Korro Bio Q3 net loss narrows to $17.55 million

Lifetime Brands Q3 net loss more than triples to $4.2 million; net sales rise to $177.7 million

Amylyx Pharma Q3 net loss bigger than expected